Search research articles
Contact Us
Filters
Showing results (191-200 of 289) with videos related to
Page
of 29
Sort By:
BJU International
|
June 30, 2018
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme
Ugo De Giorgi, Giacomo Cartenì, Diana Giannarelli, et al.
The Lancet. Oncology
|
September 15, 2023
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
Fred Saad, Noel W Clarke, Mototsugu Oya, et al.
Clinical Genitourinary Cancer
|
June 29, 2022
Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib
Roberto Iacovelli, Chiara Ciccarese, Marco Maruzzo, et al.
Cancers
|
May 14, 2022
Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study
Umberto Basso, Federico Paolieri, Mimma Rizzo, et al.
European Urology Open Science
|
October 27, 2025
Real-life Use of Cabozantinib in Front-line therapy for Metastatic Renal Cell Carcinoma: The CabFRONT Study (Meet-URO 24)
Marco Stellato, Pierangela Sepe, Enrico Bronte, et al.
Targeted Oncology
|
August 2, 2021
Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study
Matteo Santoni, Francesco Massari, Enrique Grande, et al.
European Urology
|
October 8, 2025
Erdafitinib in Patients with High- and Intermediate-risk Non-muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study
Siamak Daneshmand, Renata Zaucha, James W F Catto, et al.
Tumori
|
November 30, 2022
A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)
Giuseppe Procopio, Mélanie Claps, Chiara Pircher, et al.
International Journal of Molecular Sciences
|
January 21, 2023
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)
Marco Stellato, Sebastiano Buti, Marco Maruzzo, et al.
Future Oncology (London, England)
|
May 19, 2018
Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program
Sergio Bracarda, Luca Galli, Marco Maruzzo, et al.
Page
of 29
Search research articles
Search
Showing results (191-200 of 289) with videos related to
Sort By:
Page
of 29
BJU International
|
June 30, 2018
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme
Ugo De Giorgi, Giacomo Cartenì, Diana Giannarelli, et al.
The Lancet. Oncology
|
September 15, 2023
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
Fred Saad, Noel W Clarke, Mototsugu Oya, et al.
Clinical Genitourinary Cancer
|
June 29, 2022
Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib
Roberto Iacovelli, Chiara Ciccarese, Marco Maruzzo, et al.
Cancers
|
May 14, 2022
Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study
Umberto Basso, Federico Paolieri, Mimma Rizzo, et al.
European Urology Open Science
|
October 27, 2025
Real-life Use of Cabozantinib in Front-line therapy for Metastatic Renal Cell Carcinoma: The CabFRONT Study (Meet-URO 24)
Marco Stellato, Pierangela Sepe, Enrico Bronte, et al.
Targeted Oncology
|
August 2, 2021
Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study
Matteo Santoni, Francesco Massari, Enrique Grande, et al.
European Urology
|
October 8, 2025
Erdafitinib in Patients with High- and Intermediate-risk Non-muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study
Siamak Daneshmand, Renata Zaucha, James W F Catto, et al.
Tumori
|
November 30, 2022
A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)
Giuseppe Procopio, Mélanie Claps, Chiara Pircher, et al.
International Journal of Molecular Sciences
|
January 21, 2023
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)
Marco Stellato, Sebastiano Buti, Marco Maruzzo, et al.
Future Oncology (London, England)
|
May 19, 2018
Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program
Sergio Bracarda, Luca Galli, Marco Maruzzo, et al.
Page
of 29